Biography
Driving innovation in precision medicine, implementation science, and health system transformation, as well as basic, translational and clinicalresearch. Passionate about defining value and shifting healthcare fromreactive to proactive. Skilled in forging strategic partnerships acrosshealthcare, academia, and industry. Led multi-million-dollar initiatives, established and scaled research centers, clinics, and programs. Successfully secured tens of millions in competitive funding, withimpactful publications and invited lectures across six continents toadvance personalized, proactive, value-based care and research.

Biography
Born and raised in Scotland, Euan Angus Ashley graduated with 1st class Honors in Physiology and Medicine from the University of Glasgow. He completed medical residency and a PhD in molecular cardiology at the University of Oxford before moving to Stanford University where he trained in cardiology and advanced heart failure joining the faculty in 2006. His group is focused on the application of genomics to medicine. In 2010, he led the team that carried out the first clinical interpretation of a human genome. The paper published in the Lancet was the focus of over 300 news stories, became one of the most cited articles in clinical medicine that year, and is currently featured in the Genome Exhibition at the Smithsonian in DC. The team extended the approach in 2011 to a family of four and now routinely apply genome sequencing to the diagnosis of patients at Stanford hospital where Dr Ashley directs the Clinical Genome Service and the Center for Inherited Cardiovascular Disease. Dr Ashley is a recipient of the National Innovation Award from the American Heart Association (A HA) and a National Institutes of Health (NIH) Director’s New Innovator Award. He is a Principal Investigator of the Myocardial Applied Genomics Network (MA Gnet), a member of the leadership group of the A HA Council on Functional Genomics, and a member of the Institute of Medicine (IOM) of the National Academy of Sciences Roundtable on Translating Genomic-Based Research for Health. He is a peer reviewer for the NIH and the A HA as well as journals including Nature, the New England Journal of Medicine, the Lancet and the Journal of Clinical Investigation,. He is co-founder of, and advisor to, Personalis, Inc, a Menlo Park based genetic diagnostics company.

Biography
Genomics and healthcare leader building clinical and population solutions supporting the healthcare ecosystem. Numerous precision medicine leadership roles in leading health systems, molecular diagnostics, therapeutic development, and genomics life science. Currently leading Market Access at Illumina.

Biography
Kevan is the A VP and administrative leader of Precision Medicine at Ochsner Health in New Orleans, where he leads innovative efforts to expand access to genomic testing across the systemand beyond oncology. With over 20 years of experience in Information Services, he brings a unique blend of clinical, technical, and operational insight to the challenge of scaling personalized medicine. At Ochsner, Kevan has driven the system-wide rollout of pharmacogenomics (PGx), rapid whole genome sequencing (WGS) in the NICU, and expanded somatic testing for cancer patients. His expertise lies in developing solutions that integrate seamlessly into clinical workflows while addressing key barriers to care such as cost, provider education, and patient access. Currently, Kevan is leading the development of a Hereditary Cancer and High-Risk program. His work reflects a deep commitment to delivering precision medicine at scale, with the patient experience always at the center.

Biography
Trish Brown is a board-certified genetic counselor and accomplished healthcare executive with deep expertise in commercialization, utilization management, market access, government affairs, and revenue cycle strategy. She bridges clinical insight with business strategy to expand access to precision medicine and improve outcomes for patients and providers. Trish has held leadership roles at industry leaders including CVS Health, Illumina, and Lab Corp, and has contributed to the success of innovative startups such as DNA Direct, Fabric Genomics, and BeaconLBS. Her career reflects a commitment to advancing genomic medicine through strategic partnerships, policy advocacy, and scalable reimbursement solutions.

Biography
David Lanfear, is Co-Director of the Center for Individualized and Genomic Medicine Research (CIGMA), a practicing transplant cardiologist, and a clinician-scientist focused on precision medicine and genomics, as well as an active clinical trialist with experience in single and multicenter trials. He has been continuously funded by the NIH for his entire career and has produced more than 190 published manuscripts, reaching high-impact journals including JAMA, NEJM, and Nature: Medicine. He is nationally recognized in academic medicine previously serving on the HFSA Board of Directors, and A CC Heart Failure and Transplant Committee, and currently is on the A HA Genomics and Precision Medicine leadership committee. He is a standing member of NIH grant review panel (CCHS), an Associate Editor at Circulation: Heart Failure, has previously served as associate editor for JCF, and currently serves on the editorial boards of JACC: Heart Failure, Heart Failure Reviews, JACC: Cardio-Oncology, and JACC: Basic to Translational Science.

Biography
Sarah has more than 20 years of industry experience in leading RD organizations, CLIA and GLP laboratories, device manufacturing, consortiums, assessment and implementation of technology strategies, and development of in vitro diagnostics. In addition, she continuously works to further education and awareness in Precision Medicine and Companion Diagnostic spaces. Prior to joining BMS, Sarah was the Vice President, Precision Medicine Companion Diagnostics for Celgene, where she foundedtheir Precision Medicine Organization in 2016. She joined Celgene after having held the position as the Global Head of Future Precision Medicine for Novartis, where the team submitted and gained approval for multiple Health Authority applications; including the first pre-market approval for a distributable NGS CDx. Sarah has also held multiple roles withincreasingresponsibility within Johnson and Johnson (JNJ) including Global Head of Operations, Assay Program Leader for Companion Diagnostics Center of Excellence, Director of Materials Process Development and Enabling Technologies.

Biography
A world-renowned scientist and recipient of the National Medal of Science in 2011, Dr. Leroy Hood co-founded the Institute for Systems Biology (ISB) in 2000 and served as its first President from 2000-2017. In 2021, he founded Phenome Health, a non-profit research organization dedicated to contributing solutions to the major challenges causing a crisis in healthcare. In September 2023, Dr. Hood joined the Buck Institute for Research on Aging as Chief Innovation Officer and Distinguished Professor. Dr. Hood is a member of the National Academy of Sciences, the National Academy of Engineering, and the National Academy of Medicine. Of the more than 6,000 scientists worldwide who belong to one or more of these academies, Dr. Hood is one of only 20 people elected to all three. He is also a member of the Inventors Hall of Fame for inventing automated DNA sequencing.

Talk

Biography
Howard Jacob, Ph.D. is Vice President and Head of Quantitative Medicine & Genomics at AbbVie, where he leads enterprise-wide efforts to integrate genomics, clinical data, and advanced analytics to accelerate drug discovery and improve patient outcomes. Since joining AbbVie in 2018, he has guided one of the industry’s largest genomics research programs, supporting access to more than one million genomes and helping establish AbbVie’s Convergence data integration platform. Prior to AbbVie, Howard led clinical teams at the world’s first standalone genomic medicine clinic and whole-genome sequencing laboratory. He has authored over 300 peer-reviewed publications, founded four companies, and served on advisory boards across academia and industry. His team became the first in the world to use genome sequencing to save a patient’s life in 2010. He and his team recently published “Common Diseases in Clinical Cohorts - Not Always What They Seem”. N Engl J Med. 2025 Oct 23.

Talk

Biography
Susanne brings a wealth of experience to her role in leading a global team of precision medicine industry experts dedicated to enhancing the testing ecosystem to help patients capitalize on new breakthrough personalized medications. Susanne's journey in molecular pathology has been marked by notable achievements, including spearheading several global launches of companion diagnostic products. As a leading author of the Practice Gaps Study, Susanne played a pivotal role in identifying 7 key clinical Practice Gaps contributing to patient leakage, and her impactful contributions to the field have earned her a well-deserved place among the Pharma Voice 100 list of transformational leaders in life sciences.

Biography
Howard J. Jacob, Ph. D., brings decades of genome knowledge from academiaand the clinical setting to address the current state of whole genomesequencing and its potential for both patients and those interested inlearning more about their own DNA. Jacob is the Vice President and Head of Genomics and Data Integration at AbbVie and Distinguished Research Fellowand member of the scientific Governing Board. He joined AbbVie in January2019 to lead one of the largest Genomics Research Center efforts in thefield with access to over one million genomes and clinical data. Inaddition, he leads AbbVies RD-wide Data Integration Program (called Convergence) which brings together all types of data to create knowledge tosolve and ultimately improve treatment for patients. The Convergence teamrecently launched the AbbVie Research Collaborative, a health data platformthat enables patients to share their health data with AbbVie researchers tohelp advance the development of new medicines. Jacob earned his Ph. D. at theuniversity of Iowa and then completed a post-doctorate with Eric Lander and Victor Dzai at MIT, Harvard, and Stanford. Prior to his work at AbbVie, he led the clinical teams at the worlds first stand-alone genomic medicineclinic, as well as a whole genome clinical sequencing lab. Jacob haspublished over 250 peer-reviewed articles. He founded four companies and ison the advisory boards for numerous academic and commercialorganizations. As a pioneer and leader in genomics, in 2009, Howard and his team at the Medical College of Wisconsin were the first in the world to usegenomic sequencing to save the life of a patient. Nicholasstory was highlighted in a Pulitzer Prize winning series in the Milwaukee Journal Sentinel.

Biography
As Vanderbilt University Medical Center’s (VUMC) CEO and medical school dean since 2009, Dr. Balser has led health system expansion from two to six regional campuses housing eight hospitals and over 2000 licensed beds. With over 45,000 employees, annual operating income has grown from two to $9 billion, while annual visits at over 200 ambulatory locations now exceed 4 million from communities nationwide. VUMC houses the nation’s highest volume heart transplant program and the largest for all solid organs; the Mid-South’s largest NCI-designated comprehensive cancer center; and the Southeast’s highest ranked children’s hospital. The medical center provides advanced training to nearly 1300 physicians in over 200 specialties and ranks #5 in the Blue Ridge Institute for Medical Research rankings of NIH funding for US medical schools. The nation’s academic leader in health information technology and precision medicine, VUMC hosts the Data and Research Support Center for NIH’s “All of Us” program, gathering DNA from one million Americans for the discovery of new diagnoses and cures. An engineering graduate of Tulane and 1990 MD/PhD graduate of Vanderbilt, Dr. Balser trained in anesthesiology, cardiac anesthesiology and critical care at Johns Hopkins. There he led an NIH-funded research program aimed at genetic causes of cardiac rhythm disorders. Returning to VUMC as Associate Dean in 1998, he was anesthesiology chairman from 2001-2004 and chief research officer from 2004- 2009. In 2015-16, Dr. Balser led the medical center’s $1.2B public debt issuance and historic restructuring with Vanderbilt University to establish VUMC as a legally and financially independent, not- for-profit TN corporation. As President and CEO, he is a director at VUMC and also at CVS Health where he chairs the Medical Affairs & Technology committee. Elected to the National Academy of Medicine (NAM) in 2008, he served as an NAM governing council member from 2018 - 2024.

Talk

Biography
Born and raised in Scotland, Euan Angus Ashley graduated with 1st class Honors in Physiology and Medicine from the University of Glasgow. Hecompleted medical residency and a PhD in molecular cardiology at the University of Oxford before moving to Stanford University where he trainedin cardiology and advanced heart failure joining the faculty in 2006. Hisgroup is focused on the application of genomics to medicine. In 2010, he led the team that carried out the first clinical interpretation of a humangenome. The paper published in the Lancet was the focus of over 300 newsstories, became one of the most cited articles in clinical medicine thatyear, and is currently featured in the Genome Exhibition at the Smithsonianin DC. The team extended the approach in 2011 to a family of four and nowroutinely apply genome sequencing to the diagnosis of patients at Stanfordhospital where Dr Ashley directs the Clinical Genome Service and the Center for Inherited Cardiovascular Disease. Dr Ashley is a recipient of the National Innovation Award from the American Heart Association (A HA) and a National Institutes of Health (NIH) Directors New Innovator Award. He is a Principal Investigator of the Myocardial Applied Genomics Network (MA Gnet), a member of the leadership group of the A HA Council on Functional Genomics, and a member of the Institute of Medicine (IOM) of the National Academy of Sciences Roundtable on Translating Genomic-Based Research for Health. He isa peer reviewer for the NIH and the A HA as well as journals including Nature, the New England Journal of Medicine, the Lancet and the Journal of Clinical Investigation,. He is co-founder of, and advisor to, Personalis, Inc, a Menlo Park based genetic diagnostics company.

Biography
Jacob Thaysen is Chief Executive Officer of Illumina. Prior to joining the company in 2023, Thaysen served as president of the Life Sciences and Applied Markets Group and Diagnostic and Genomics Group at Agilent; corporate vice president of RD at Dako; and management consultant at Copenhagen Consultancy Company (now Bain Co). Early in his career, he was founder and chief technology officer of Cantion, a research and defense application development company based in Denmark. Thaysen is Chairman of the A LDA Board (Analytical, Life Science and Diagnostic Association) and is a San Diego Chapter member of the American Cancer Societys CE Os Against Cancer. Thaysen holds an MSc and PhD in physics from the Technical University of Denmark.

Biography
Premal Shah, Ph. D., is the CEO of My Ome, a genomics innovation company focused on preventive health through whole genome sequencing and polygenic risk scoring. With over 20 years of experience in biotech and healthcare, he is dedicated to advancing personalized medicine and genomics-driven health solutions. Previously, Premal was Co-Founder President at Ciitizen, a digital health company empowering patients with their own health data, where he oversaw operations and strategic development, including go-to-market strategies. Ciitizen was acquired by Invitae. Before Ciitizen, he served as CEO of Applied Proteomics, a company pioneering a blood-based colorectal cancer diagnostic test. Prior to that, he led corporate development at Genomic Health (now part of Exact Sciences). Premal began his career as a management consultant at Booz Company, focusing on front-office strategies. He holds a Ph. D. in computational biology from the California Institute of Technology, with several publications in the field.

Biography
As Vanderbilt University Medical Center’s (VUMC) CEO and medical school dean since 2009, Dr. Balser has led health system expansion from two to six regional campuses housing eight hospitals and over 2000 licensed beds. With over 45,000 employees, annual operating income has grown from two to $9 billion, while annual visits at over 200 ambulatory locations now exceed 4 million from communities nationwide. VUMC houses the nation’s highest volume heart transplant program and the largest for all solid organs; the Mid-South’s largest NCI-designated comprehensive cancer center; and the Southeast’s highest ranked children’s hospital. The medical center provides advanced training to nearly 1300 physicians in over 200 specialties and ranks #5 in the Blue Ridge Institute for Medical Research rankings of NIH funding for US medical schools. The nation’s academic leader in health information technology and precision medicine, VUMC hosts the Data and Research Support Center for NIH’s “All of Us” program, gathering DNA from one million Americans for the discovery of new diagnoses and cures. An engineering graduate of Tulane and 1990 MD/PhD graduate of Vanderbilt, Dr. Balser trained in anesthesiology, cardiac anesthesiology and critical care at Johns Hopkins. There he led an NIH-funded research program aimed at genetic causes of cardiac rhythm disorders. Returning to VUMC as Associate Dean in 1998, he was anesthesiology chairman from 2001-2004 and chief research officer from 2004- 2009. In 2015-16, Dr. Balser led the medical center’s $1.2B public debt issuance and historic restructuring with Vanderbilt University to establish VUMC as a legally and financially independent, not- for-profit TN corporation. As President and CEO, he is a director at VUMC and also at CVS Health where he chairs the Medical Affairs & Technology committee. Elected to the National Academy of Medicine (NAM) in 2008, he served as an NAM governing council member from 2018 - 2024.

Biography
Niall Lennon has been with the Broad Institute for over 20 years and has contributed to the development of applications for every major next generation sequencing platform across a range of fields. In 2013, Dr. Lennon built Broad Clinical Labs, a CLIACAP licensed clinical laboratory at the Broad, to facilitate return of results to patients and to support clinical trials. Dr. Lennon has led efforts to achieve FDA approval for both large-scale genomics projects (as co-Chair of the regulatory working group for NI Hs All of Us Research Project) and for Broads own clinical diagnostic for COVID-19 testing process that delivered 37 million diagnostic test results to people in the New England region during the pandemic. In 2025, Niall led a team that collaborated with Roche to achieve a world record for the fastest human genome sequenced.

Biography
As Vanderbilt University Medical Center’s (VUMC) CEO and medical school dean since 2009, Dr. Balser has led health system expansion from two to six regional campuses housing eight hospitals and over 2000 licensed beds. With over 45,000 employees, annual operating income has grown from two to $9 billion, while annual visits at over 200 ambulatory locations now exceed 4 million from communities nationwide. VUMC houses the nation’s highest volume heart transplant program and the largest for all solid organs; the Mid-South’s largest NCI-designated comprehensive cancer center; and the Southeast’s highest ranked children’s hospital. The medical center provides advanced training to nearly 1300 physicians in over 200 specialties and ranks #5 in the Blue Ridge Institute for Medical Research rankings of NIH funding for US medical schools. The nation’s academic leader in health information technology and precision medicine, VUMC hosts the Data and Research Support Center for NIH’s “All of Us” program, gathering DNA from one million Americans for the discovery of new diagnoses and cures. An engineering graduate of Tulane and 1990 MD/PhD graduate of Vanderbilt, Dr. Balser trained in anesthesiology, cardiac anesthesiology and critical care at Johns Hopkins. There he led an NIH-funded research program aimed at genetic causes of cardiac rhythm disorders. Returning to VUMC as Associate Dean in 1998, he was anesthesiology chairman from 2001-2004 and chief research officer from 2004- 2009. In 2015-16, Dr. Balser led the medical center’s $1.2B public debt issuance and historic restructuring with Vanderbilt University to establish VUMC as a legally and financially independent, not- for-profit TN corporation. As President and CEO, he is a director at VUMC and also at CVS Health where he chairs the Medical Affairs & Technology committee. Elected to the National Academy of Medicine (NAM) in 2008, he served as an NAM governing council member from 2018 - 2024.

Biography
Dr Howard McLeod is an internationally recognized expert in precision medicine, having made novel contributions at the discovery, translation, implementation, and policy levels. Dr McLeod has been recognized as a Fellow of both the American Society of Clinical Oncology and the American College of Clinical Pharmacy. He has also been an active Board Member and or Founder for over a dozen privately held and publicly traded companies. Howard has published over 600 peer reviewed papers on pharmacogenomics, applied therapeutics, or clinical pharmacology and continues to work to advance innovative healthcare.

Biography
Driving innovation in precision medicine, implementation science, and health system transformation, as well as basic, translational and clinical research. Passionate about defining value and shifting healthcare from reactive to proactive. Skilled in forging strategic partnerships across healthcare, academia, and industry. Led multi-million-dollar initiatives, established and scaled research centers, clinics, and programs. Successfully secured tens of millions in competitive funding, with impactful publications and invited lectures across six continents to advance personalized, proactive, value-based care and research.

Biography
Dr. K. V. Venkatesh is a Professor in the Department of Chemical Engineering at IIT Bombay and a leading authority in systems biology, applying engineering systems principles to understand complex biological phenomena. Over three decades, his research has focused on uncovering the design principles that connect genotype to phenotype and developing dynamic physiology models of organs and diseases. His work has influenced areas such as drug discovery, wellness, and personalized healthcare. He has mentored over 40 PhD scholars, published nearly 250 papers, and is a Fellow of the National Academy of Sciences, India and is a receipient of several prestigious national awards. Building on this foundation, Dr. Venkatesh founded Metflux Research, a systems-biology-driven precision health company offering personalization and RD solutions that integrate multi-modal biology to enable predictive, preventive, and personalized healthcare. The platform is live in prominent Wellness, Neutra and Healthfood enterprises.

Talk
This talk presents a systems-biology approach that integrates genetic, microbiome, multi-omic, wearables, and clinical data to generate pathway-resolved physiological insights. The expert system illustrates how combining biological knowledge with analytical reasoning provides a totality of evidence for individual immuno-metabolic physiological states, supporting precision-care decision-making.

Biography
Mark Atalla currently serves as the Deputy Assistant Secretary for Technology Policy/Deputy National Coordinator at HHS. Previously, he was part of a team using AI to change behavior and reduce health spend, the CMS Administrator's Senior Advisor for Innovation, and in operational roles at Medco/Express Scripts and Fresenius. He has a PharmD from the University of Florida and an MBA from Yale.

Biography
Daryl Pritchard, Ph. D., is the interim President and Senior Vice President for Science Policy at the Personalized Medicine Coalition (PMC), where he leads the Coalitions efforts to develop and promote optimal science-related policies and to increase awareness and understanding of personalized medicine among health care providers, patients, policymakers, and other stakeholders. This includes working to identify and address barriers to the clinical adoption of personalized medicine, including the development and promotion of appropriate clinical, infrastructure, regulatory, and payment policies. As interim President, Daryl serves as the executive leader of the Personalized Medicine Coalition managing all aspects of the organization including operations, member and partner development, communications, strategic planning, and business development as we drive our mission in education, advocacy and evidence development to advance personalized medicine.

Biography
Eric D. Green leads Illumina’s medical strategy to advance clinical genomics, broaden access to precision medicine, and increase diversity in genomic data. He joined Illumina effective February 2, 2026, bringing unparalleled gravitas from a career that helped shape modern genomics.Dr. Green is widely regarded as one of the most influential genomics leaders of his generation. Before Illumina, he served for over three decades at the National Human Genome Research Institute (NHGRI) at the U.S. National Institutes of Health, including as Director from 2009 to 2025, where he steered the transformation of genomics from research into foundational medicine and public health.A physician-scientist trained at Washington University School of Medicine (M.D., Ph.D.), Green played a central role in the Human Genome Project and has authored hundreds of publications.

Biography
Dr. Hampton joined Southern Research in 2023, bringing more than 15 years of industry and academic experience developing novel sequencing methods and computational workflows for multi-omic and clinical data supporting RWD/RWE, precision medicine, therapeutic target discovery, and clinical trial matching. Before Southern Research, he served as Vice President of Bioinformatics and Biostatistics at Aster Insights, a health informatics company advancing cancer care through precision medicine. He also led Memorial Sloan Kettering Cancer Center’s Platform Informatics core facility, overseeing automated analysis pipelines that transform next-generation sequencing data into high-confidence results for clinical and research use. Earlier, he was a Research Assistant Professor at the Human Genome Sequencing Center at Baylor College of Medicine, focusing on the genetics of pediatric cancers. Dr. Hampton earned a B.S. in biochemistry and an M.S. in computer science from New Mexico State University, and a Ph.D. in Structural and Computational Biology and Molecular Biophysics from Baylor College of Medicine.

Biography
Dr. Gordon is Clinical Director of Providence Health’s Population Genomics Program, guiding clinical and research protocols in genomic medicine across Providence’s 50-hospital network. As principal investigator for the Geno4Me study and studies on cell-free DNA multicancer early detection blood tests, she has enrolled thousands of high-risk patients in prevention and early detection efforts. Regionally, she directs the Clinical Genetics & Genomics Program for Providence Southern California, overseeing services in Los Angeles and Orange Counties. Dr. Gordon is a professor of genetics at Saint John’s Cancer Institute and of medicine at UCLA Geffen School of Medicine. She earned her bachelor’s degree from Tulane University and her MS and MD from UC Irvine, followed by residency and a genetics fellowship at UCLA. Board certified in internal medicine and medical genetics, she co-authored “Positive Results,” an award-winning book for women at genetic risk for breast or ovarian cancer.

Biography
Dr. Ronit Yarden is a translational scientist and genetic epidemiologist with a special interest in advancing precision medicine and improving patient outcomes for cancer and cardiovascular diseases. Dr. Yarden holds leadership roles in the NHLBI Trans-Omics for Precision Medicine (TOPMed) program and the Strong Heart Study (SHS). She also manages a research portfolio focused on large-scale genomics and multiomics studies, and the use of AI/ML, aimed at identifying biomarkers and risk factors related to cardiovascular health and disease. Prior to joining NIH, Dr. Yarden held the position of Senior Director of Medical Affairs and Research Strategy at a patient advocacy group leading their population health research program, funding initiatives and health policy advocacy. Dr. Yarden was also a full-time faculty at Georgetown University and a full member of the Lombardi Comprehensive Cancer Center where research in her lab focused on hereditary breast cancer and drug discovery targeting the DNA Damage Response pathways.

Biography

Biography
David is the CTO for Verily Workbench, a secure research environment for governing and analyzing multimodal biomedical data. He is a PI for the Data and Research Center, and a member of the Steering Committee, of the NIH All of Us Research Program. He serves on advisory boards for UK Biobank, NIH Bridge2AI, ELIXIR, and Vanderbilt University Medical Center. He served on the NIH Advisory Committee to the Director, where he co-chaired the AI Working Group. He is a member of the Board of Directors, and a former co-chair of the Cloud Workstream, of the Global Alliance for Genomics and Health (GA4GH). He previously worked at Google, where he founded the Google Genomics team. Prior to joining Google in 2006, he successfully started two companies: Eloquent in 1995 (IPO 2000), which used rich media to power business communications, and Verity in 1988 (IPO 1995), which did full-text search.